[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100518103":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":12,"locations":25,"responsibleParty":47,"collaborators":12,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":12,"maxAge":12,"enrollmentInfo":59,"targetDuration":12,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":71,"overallStatus":28,"whyStopped":12,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Erasmus Medical Center","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Care-as-usual","NO_INTERVENTION","In the ''care-as-usual'' arm, all patients undergo 'care-as-usual', i.e. a cystoscopy and upper tract imaging (ultrasound or CT-scan)",null,{"label":14,"type":15,"description":16,"interventionNames":17},"'Urine-first' strategy","EXPERIMENTAL","In the intervention arm, the urine test is used to triage patients for a diagnostic workup ('urine-first' strategy). Only patients with an abnormal test result undergo cystoscopy and upper tract imaging.",[18],"Diagnostic Test: urine-first strategy",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"DIAGNOSTIC_TEST","urine-first strategy","Only patients with an abnormal urine test result undergo a diagnostic workup, i.e. cystoscopy and upper-tract imaging.",[14],[26],{"facility":27,"status":28,"city":29,"state":12,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"SeARCH-trial Pijpers","RECRUITING","Rotterdam","3015GD","Netherlands","NL",{"type":34,"coordinates":35},"Point",[36,37],4.47917,51.9225,{"lat":37,"lon":36},[40,45],{"name":41,"role":42,"phone":43,"phoneExt":12,"email":44},"J.L. Boormans, Prof. MD","CONTACT","0031 107040251","search.studie@erasmusmc.nl",{"name":46,"role":42,"phone":12,"phoneExt":12,"email":12},"O.M. Pijpers, MD",{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"PRINCIPAL_INVESTIGATOR","J.L. Boormans, MD PhD","Professor","100518103","safely-reduce-cystoscopic-evaluations-for-hematuria-patients-100518103",false,"NCT06026189","Safely Reduce Cystoscopic Evaluations for Hematuria Patients","SeARCH","Inclusion Criteria:\n\n* Microscopically confirmed microscopic hematuria of voided urine defined as ≥3 erythrocytes per high power field\n* Male patients ≥40 years\n* Female patients ≥50 years\n\nExclusion Criteria:\n\n* History of urothelial bladder- or urinary tract cancer\n* Presence of macroscopic (visible) hematuria\n* Woman who is or may be pregnant","ALL",{"count":60,"type":61},1100,"ESTIMATED","INTERVENTIONAL",[64],"NA","The SeARCH-trial assess the clinical impact of a molecular urine test as a 'urine-first' strategy in the diagnostic workup of patients presenting with microscopic hematuria.",[67,68,69,70],"Hematuria","Urothelial Neoplasm","Urothelial Carcinoma","Bladder Cancer",[72,67,69,70],"Urinary biomarker","2023-08-30",{"date":75,"type":76},"2023-09-06","ACTUAL",{"date":78,"type":76},"2023-05-31",{"date":80,"type":61},"2027-05-31",{"name":5,"class":6},1]